Gilead, LEO Pharma and Strategic Partnership
Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to ...
In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...
The stock's rise snapped a five-day losing streak.
After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...
Zacks.com on MSN2d
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to KnowIn the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.
This was the stock's fourth consecutive day of losses.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project ...
Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback